Gastrointestinal Cancer | Specialty

Radiographic Monitoring after Treatment in HCC

April 22nd 2016

Radioembolization in HCC

April 22nd 2016

Chemoembolization in Hepatocellular Carcinoma

April 22nd 2016

Resectability of HCC

April 22nd 2016

Diagnostic Workup for HCC

April 22nd 2016

Risk Factors for Hepatocellular Carcinoma

April 22nd 2016

Multidisciplinary Care in Hepatocellular Carcinoma

April 22nd 2016

Dr. Berger on Noninvasive Screening Tool for CRC

April 19th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

Dr. Udit Verma on Regorafenib in Patients With mCRC

April 13th 2016

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

Biomarker Leads to New Potential CRC Treatment

April 13th 2016

Deficiency in the protein NOD-like receptor X1 (NLRX1) could represent a potential biomarker to predict response to therapies in patients with colorectal cancer.

Expert Discusses Microsatellite Instability, Immunotherapy in CRC

April 11th 2016

Zsofia K. Stadler, MD, provides extensive insight on microsatellite instability in colorectal cancer, the biology of and screening for MSI tumors, and the potential impact immunotherapy could have on the treatment paradigm.

Ensituximab Shows Promise in Refractory mCRC

April 8th 2016

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer without contributing significant toxicity.

Pancreatic Cancer Survival Rates Lower in Real World Than Clinical Trials

April 8th 2016

Patients with pancreatic adenocarcinoma enrolled on clinical trials have “profoundly improved survival” compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark.

Personalized Medicine Plausible in Pancreatic Cancer

April 7th 2016

Genomic and proteomic characterization of pancreatic cancer tumors can effectively be used to prescreen patients for clinical trials exploring molecularly matched targeted therapies.

Dr. Deirdre Cohen on Emerging Agents in Gastric Cancer

April 6th 2016

Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer

April 6th 2016

Colin Weekes, MD, PhD, gives insight into the current state and future directions for neoadjuvant therapy for pancreatic cancer.

Case Study Suggests Regorafenib Remains Effective Beyond Progression for mCRC

April 5th 2016

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Earlier Nab-Paclitaxel/Gemcitabine Explored in Pancreatic Cancer

April 4th 2016

A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.

NCCN Guideline Expands Locoregional Treatment Candidates in HCC

April 1st 2016

Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma.

Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC

March 31st 2016

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).